Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptorblockers

Clinical Nephrology

Volumn 72, Issue 5, 2009, Pages 353-359

  Choi, S ^a   Lee, D ^a   Jeong, K H ^a   Moon, J Y ^a   Lee, S H ^a   Lee, T W ^a   Ihm, C G ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Angiotensin receptor blocker; IgA nephropathy prognosis; Steroid

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; IMMUNOGLOBULIN A; IRBESARTAN; LOSARTAN; PREDNISOLONE; RAMIPRIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GASTRITIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MALE; PROGNOSIS; PROTEINURIA;

EID: 70350783645     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72353     Document Type: Article

References (28)

1. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991; 36: 53-59.
2. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006; 69: 1934-1938.
3. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38: 728-735.
4. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994; 23: 247-254.
5. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007; 18: 1880-1888.
6. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, Imbasciati E, Ragni A, Bertoli S, Fogazzi G. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med. 1986; 59: 363-378.
7. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36: 227-237.
8. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002; 17: 1197-1203.
9. Horita Y, Tadokoro M, Taura K, Ashida R, Hiu M, Taguchi T, Furusu A, Kohno S. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail. 2007; 29: 441-446.
10. Ihm CG, Lee SH, Lee SH, Kim YH, Lee TW, Kim MJ. Combined treatment of prednisolone and angiotensin II receptor blocker in IgA nephropathy. J Am Soc Nephrol. 2003; 14: 752A.
11. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003; 41: 972-983.
12. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997; 29: 526-532.
13. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a longterm controlled trial. Clin Nephrol. 1986; 26: 174-180.
14. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, Park SY, Han JS, Kim S, Lee JS. Histological grad ing of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant. 2005; 20: 342-348.
15. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Chronic Kidney Disease Epidemiology: expressing the modification of diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772.
16. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese: clinical and pathological perspectives. Nephrol Dial Transplant. 2007; 17: 64-69.
17. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006; 47: 751-760.
18. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccala A, Zucchelli P. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994; 9: 265-269.
19. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004; 15: 157-163.
20. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003; 14: 1578-1583.
21. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997; 8: 199-207.
22. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18: 3177-3183.
23. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology. 2004; 9: 177-185.
24. Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007; 106: 157-161.
25. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000; 35: 194-201.
26. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, Horikoshi S, Tomino Y. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int. 2007; 72: 319-327.
27. Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K, Hirayama A, Yoh K, Tomida C, Hirayama K, Suzuki S, Kobayashi M, Nagata M, Koyama A. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med. 2001; 40: 697-702.
28. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, Ohno Y, Inaba Y, Sakai H. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006; 21: 2800-2808.